Under the terms of the license option agreement, originally announced in October 2021, Voyager previously received a $30 million upfront payment and is entitled to receive a $10 million option exercise payment. Voyager is eligible to receive potential future development, regulatory and commercialization milestone payments of up to $115 million, sales milestones of up to $175 million, and mid- to high-single-digit tiered royalties in connection with Pfizer’s use of its capsid in development and commercialization of a gene therapy for a rare neurologic target.
Evaxion Announces Initial Phase 2 Clinical Data On Its Personalized Cancer Vaccine EVX-01
Initial EVX-01 Phase 2 data confirms the strong Phase 1 resultsAfter undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive
